Breast Cancer: CALGB 49907 (Hematology Oncology Associates)

CALGB 49907 A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens Cyclophosphamide, Methotrexate and Fluorouracil – (CMF) of doxorubicin and Cyclophosphamide – (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or High-Risk Node-Negative Breast Cancer.

Objective

To compare the effectiveness of standard chemotherapy regimens (Cyclophosphamide, Methotrexate and Fluorouracil [CMF] or Doxorubicin and Cyclophosphamide [AC]) with single agent Capecitabine with respect to disease-free survival in women 65 years and older with local and regional breast cancer.

Principal Investigator(s)
Shobha Chitneni

Clinical Trial Categories

  • Cancer
  • Breast Cancer
Sponsor(s)
Cancer and Leukemia Group B
Contact
Katy D'Aprile, RN, BSN at 563-355-7733

Location

  • Hematology Oncology Associates of the Quad Cities
    1351 East Kimberly Road
    Suite 100
    Bettendorf, IA 52722

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email